Recurrence of endometrial cancer in a hysterectomised patient treated with tamoxifen for breast cancer: a case report-Reference-Cited by-同舟云学术

Recurrence of endometrial cancer in a hysterectomised patient treated with tamoxifen for breast cancer: a case report

Published:2020-10-12 Issue:11 Volume:113 Page:454-456
ISSN:0141-0768
Container-title:Journal of the Royal Society of Medicine
language:en
Short-container-title:J R Soc Med

Author:

Woolas James¹^ORCID,Davis Megan²,Rahimi Siavash³⁴⁵

Affiliation:

1. Peninsula School of Medicine and Dentistry, Plymouth University, Plymouth PL6 8BU, UK

2. Torbay and South Devon Foundation NHS Trust, Torquay TQ2 7AA, UK

3. Frontier Pathology-Histopathology, Brighton and Sussex University Hospitals NHS Trust, Brighton BN2 5BE, UK

4. School of Pharmacy, University of Portsmouth, Portsmouth PO1 2DT, UK

5. School of Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK

Abstract

Tamoxifen exposure is a recognised risk for primary endometrial cancer. This case serves as a reminder to meticulously check the past medical history and inform patients of the risk-benefit of treatment as part of a shared-decision making process.

Publisher

SAGE Publications

Subject

General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/0141076820961087

Reference6 articles.

1. Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer

2. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes

3. Tamoxifen-induced endometrial carcinoma after a lag of 14 years

4. Natural history of recurrences in endometrial carcinoma

5. Is time to recurrence after hysterectomy predictive of survival in patients with early stage endometrial carcinoma?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Common Multiple Primary Cancers Associated With Breast and Gynecologic Cancers and Their Risk Factors, Pathogenesis, Treatment and Prognosis: A Review;Frontiers in Oncology;2022-06-08

2. An Update on the Effect of Natural Products on Oncogenic Transcription Factors in Triple Negative Breast Cancer;Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics;2022-03-18

3. Tamoxifen;Reactions Weekly;2020-11